Skip to main content
. 2018 Apr;59(5):2154–2166. doi: 10.1167/iovs.17-23282

Figure 8.

Figure 8

Effects of Ad5. Null, Ad5.TGFβ2, and Ad5.Cre on IOP in B6;129S1-Bambitm1Jian/J mice. Mice were injected intravitreally with Ad5.Null, Ad5.Cre, Ad5.TGFβ2, or Ad5.TGFβ2 + Ad5.Cre (2.5 × 107 pfu). Day of injection was designated as day 0. The contralateral eye of each mouse was uninjected and served as a paired control. (A) Ad5.Null did not induce ocular hypertension at any time point compared to the contralateral eye (n = 7). (B–D) Injection with Ad5.Cre, Ad5.TGFβ2, or Ad5.TGFβ2 + Ad5.Cre each induced ocular hypertension starting at day 7 after injection and maintained significant IOP elevation throughout the 56-day time course compared to uninjected control eyes (P < 0.01, days 7–56). (B) At day 56 after injection, IOP increased to 29.8 ± 3.2 mm Hg in Ad5.Cre–injected eyes compared to 14.2 ± 0.3 mm Hg in contralateral uninjected eyes (P < 0.001, n = 9). (C) Ad5.TGFβ2 (32.3 ± 2.6 mm Hg) had significant IOP elevation at 56 days after injection compared to 14.2 ± 0.3 mm Hg in uninjected control eyes (P < 0.001, n = 10). (D) Ad5.TGFβ2 + Ad5.Cre (32.4 ± 3.9 mm Hg) had significant IOP elevation at 56 days after injection compared to uninjected control eyes (14.1 ± 0.3 mm Hg; P < 0.001, n = 10). Statistical significance was determined by Student's paired t-test at each time point comparing the transduced eye to the contralateral uninjected control eye, **P < 0.01, ***P < 0.001 (* = compared to uninjected control).